{
    "id": 684,
    "name": "hepatocellular carcinoma",
    "source": "DOID",
    "definition": "A liver carcinoma that has_material_basis_in undifferentiated hepatocytes and located_in the liver. [url:http\\://cancergenome.nih.gov/cancersselected/LiverHepatocellularCarcinoma, url:http\\://en.wikipedia.org/wiki/Hepatocellular_carcinoma, url:http\\://www.omim.org/entry/114550]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "5005"
    ],
    "termId": "DOID:684",
    "evidence": [
        {
            "id": 1718,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FH535 demonstrated efficacy by inhibiting proliferation of liver cancer stem cells and hepatocellular carcinoma cells in culture (PMID: 24940873).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2083,
                "therapyName": "FH535",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1952,
                    "pubMedId": 24940873,
                    "title": "Targeting the Wnt/\u03b2-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24940873"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 869,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tepotinib (MSC2156119J) treatment resulted in tumor regression in patient-derived xenograft models of hepatocellular cancer with high Met expression level (PMID: 25256830).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 1398,
                "therapyName": "Tepotinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7829,
                    "pubMedId": 25256830,
                    "title": "The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25256830"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 949,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Adrucil (fluorouracil) combined with interferon alfa-2b was well-tolerated and demonstrated efficacy in patients with hepatocellular carcinoma, with 25% (9/36) patients achieving complete or partial response, and a median overall survival of 19.5 months (PMID: 12560429).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4229,
                "therapyName": "Fluorouracil + Interferon alpha-2b",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1047,
                    "pubMedId": 12560429,
                    "title": "Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12560429"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1419,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Plerixafor (AMD3100) demonstrated efficacy in inhibiting cellular migration in hepatocellular carcinoma cells over-expressing CXCR4 (PMID: 25363530).",
            "molecularProfile": {
                "id": 2493,
                "profileName": "CXCR4 over exp"
            },
            "therapy": {
                "id": 1756,
                "therapyName": "Plerixafor",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1228,
                    "pubMedId": 25363530,
                    "title": "CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25363530"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1423,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, single-agent linifanib was found safe and efficacious in patients with advanced hepatocellular carcinoma (PMID: 22833179).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 797,
                "therapyName": "Linifanib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 64,
                    "pubMedId": 22833179,
                    "title": "Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22833179"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1498,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hepatocellular carcinoma cells overexpressing ID2 had decreased senstitivity to entinostat (MS-275) in culture (PMID: 23403953).",
            "molecularProfile": {
                "id": 2608,
                "profileName": "ID2 over exp"
            },
            "therapy": {
                "id": 1541,
                "therapyName": "Entinostat",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1419,
                    "pubMedId": 23403953,
                    "title": "Susceptibility of hepatoma-derived cells to histone deacetylase inhibitors is associated with ID2 expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23403953"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1546,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, overexpression of Mst1 in hepatocellular carcinoma cells decreased proliferation, increased apoptosis, and increased sensitivity to cisplatin in cell culture, suggesting that Mst1 may serve as a potential therapeutic target (PMID: 23419720)",
            "molecularProfile": {
                "id": 2666,
                "profileName": "MST1 over exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1468,
                    "pubMedId": 23419720,
                    "title": "Effect of Mst1 overexpression on the growth of human hepatocellular carcinoma HepG2 cells and the sensitivity to cisplatin in vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23419720"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1619,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, inhibition of TEAD1 ability to interact with YAP inhibited tumor growth in cultured cells and xenograft models of hepatocellular carcinoma suggesting Tead1 as a viable therapeutic target in cancer (PMID: 25384421).",
            "molecularProfile": {
                "id": 2762,
                "profileName": "TEAD1 wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1702,
                    "pubMedId": 25384421,
                    "title": "Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25384421"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1997,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Nexavar (sorafenib) improved median progression free survival to 10.7 months in patients with unresectable hepatocellular carcinoma (PMID: 19144678).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2439,
                    "pubMedId": 19144678,
                    "title": "Sorafenib for the treatment of unresectable hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19144678"
                },
                {
                    "id": 15587,
                    "pubMedId": null,
                    "title": "Nexavar (sorafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021923"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2213,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Verrucarin A treatment resulted in decreased Ncoa3 (Src-3) protein levels and inhibited growth of hepatocellular carcinoma cells in culture (PMID: 24743578).",
            "molecularProfile": {
                "id": 6301,
                "profileName": "NCOA3 over exp"
            },
            "therapy": {
                "id": 2715,
                "therapyName": "Verrucarin A",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2775,
                    "pubMedId": 24743578,
                    "title": "Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24743578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2436,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Refametinib (BAY86-9766), in combination with Nexavar (sorafenib), demonstrated more clinical benefit in hepatocellular carcinoma patients with mutant Kras than in patients with wild-type Kras (PMID: 25294897).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2221,
                "therapyName": "Refametinib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3050,
                    "pubMedId": 25294897,
                    "title": "A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25294897"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15076,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Refametinib (BAY86-9766) and Nexavar (sorafenib) combination treatment resulted in an objective response rate of 6.3% (1/16), a disease control rate of 43.8% (7/16), an overall survival of 12.7 months, and a progression-free survival of 1.5 months in patients unresectable or metastatic hepatocellular carcinoma harboring RAS (NRAS and KRAS) mutations (PMID: 29950351; NCT01915602).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2221,
                "therapyName": "Refametinib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12624,
                    "pubMedId": 29950351,
                    "title": "Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29950351"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2849,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torin 2 inhibited proliferation of hepatocellular cells in culture (PMID: 26239364).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2249,
                "therapyName": "Torin 2",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3504,
                    "pubMedId": 26239364,
                    "title": "The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26239364"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3158,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT031374 inhibited growth of a hepatocellular carcinoma cell line harboring an inactivating mutation in Axin1 in culture (PMID: 20610623).",
            "molecularProfile": {
                "id": 12071,
                "profileName": "AXIN1 inact mut"
            },
            "therapy": {
                "id": 2400,
                "therapyName": "CCT031374",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2213,
                    "pubMedId": 20610623,
                    "title": "A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20610623"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3792,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tepotinib (MSC2156119J) inhibited tumor growth in hepatocellular cancer (HCC) mouse xenograft models with MET overexpression or activation (Cancer Res April 15, 2013; 73(8 Supplement): 925)",
            "molecularProfile": {
                "id": 2096,
                "profileName": "MET act mut"
            },
            "therapy": {
                "id": 1398,
                "therapyName": "Tepotinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 529,
                    "pubMedId": null,
                    "title": "Abstract 925: The c-Met inhibitor MSC2156119J effectively inhibits growth of liver cancer models.",
                    "url": null
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3826,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PMED-1 decreased Wnt expression and decreased proliferation of hepatocellular carcinoma cells with Ctnnb1 mutations (PMID: 24819961).",
            "molecularProfile": {
                "id": 11801,
                "profileName": "CTNNB1 mutant"
            },
            "therapy": {
                "id": 3370,
                "therapyName": "PMED-1",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4232,
                    "pubMedId": 24819961,
                    "title": "Identification and characterization of a novel small-molecule inhibitor of \u03b2-catenin signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24819961"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4655,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LLL12 inhibited Stat3 phosphorylation, decreased expression of Stat genes, and reduced growth of human hepatocellular cancer cell lines in culture and in xenografts (PMID: 25883212).",
            "molecularProfile": {
                "id": 17606,
                "profileName": "STAT3 wild-type"
            },
            "therapy": {
                "id": 3592,
                "therapyName": "LLL12",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4664,
                    "pubMedId": 25883212,
                    "title": "LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25883212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4768,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of LCL161 and Taxol (paclitaxel) inhibited proliferation of hepatocellular carcinoma cells in culture (PMID: 24976294).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3642,
                "therapyName": "LCL161 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4718,
                    "pubMedId": 24976294,
                    "title": "Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24976294"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5048,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilenya (fingolimod) worked synergistically with Nexavar (sorafenib) to inhibit growth and induce apoptosis in hepatocellular carcinoma cell lines in culture (PMID: 26516583).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3739,
                "therapyName": "Fingolimod + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4862,
                    "pubMedId": 26516583,
                    "title": "FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26516583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5254,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a phase II trial, PI-88 treatment significantly improved survival for up to 3 years in hepatocellular carcinoma patients compared to control, as evidenced by increased recurrence-free rate (63% vs 50%) and postponed time to recurrence at the 36th percentile by 78% (PMID: 25170226).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3802,
                "therapyName": "PI-88",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4969,
                    "pubMedId": 25170226,
                    "title": "Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25170226"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5258,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Lenvima (lenvatinib) resulted in safety and preliminary efficacy in patients with hepatocellular carcinoma, demonstrating a partial response in 15% (3/20) of patients and tumor regression in 70% (14/20) (PMID: 26500236).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4972,
                    "pubMedId": 26500236,
                    "title": "Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26500236"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10380,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Lenvima (lenvatinib) treatment resulted in partial response in 37% (17/46) and stable disease in 41% (19/46) of patients with advanced hepatocellular carcinoma, and a median overall survival of 18.7 months (PMID: 27704266).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8405,
                    "pubMedId": 27704266,
                    "title": "Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27704266"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14984,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (REFLECT) that supported FDA approval, Lenvima (lenvatinib) demonstrated activity comparable to Nexavar (sorafenib), resulted in a median survival time of 13.6 months in patients with unresectable hepatocellular carcinoma (PMID: 29433850; NCT01761266).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11941,
                    "pubMedId": 29433850,
                    "title": "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29433850"
                },
                {
                    "id": 15578,
                    "pubMedId": null,
                    "title": "Lenvima (lenvatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206947"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5292,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with NanoHHI decreased growth and migration of hepatocellular carcinoma cells in culture, and inhibited tumor growth and metastasis in hepatocellular carcinoma cell line xenograft models (PMID: 21868763).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3818,
                "therapyName": "NanoHHI",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4993,
                    "pubMedId": 21868763,
                    "title": "Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21868763"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5406,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, OPB-31121 treatment resulted in only stable disease in 26% (6/23) of patients with advanced hepatocellular carcinoma, and was considered insufficient for clinical efficacy (PMID: 25676869).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3852,
                "therapyName": "OPB-31121",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5048,
                    "pubMedId": 25676869,
                    "title": "Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25676869"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5910,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, U3-1784 inhibited growth of FGF19-positive hepatocellular carcinoma cell lines in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #3852).",
            "molecularProfile": {
                "id": 21999,
                "profileName": "FGF19 positive"
            },
            "therapy": {
                "id": 3980,
                "therapyName": "U3-1784",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5194,
                    "pubMedId": null,
                    "title": "U3-1784, a human anti-FGFR4 antibody for the treatment of cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=800c7dcf-322a-4e97-830b-0887c43f4108&cKey=4b473f86-5e89-431f-b228-b5a1a902ce34&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5911,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGF19-negative hepatocellular carcinoma cell lines were insensitive to U3-1784 induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #3852).",
            "molecularProfile": {
                "id": 21998,
                "profileName": "FGF19 negative"
            },
            "therapy": {
                "id": 3980,
                "therapyName": "U3-1784",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5194,
                    "pubMedId": null,
                    "title": "U3-1784, a human anti-FGFR4 antibody for the treatment of cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=800c7dcf-322a-4e97-830b-0887c43f4108&cKey=4b473f86-5e89-431f-b228-b5a1a902ce34&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6020,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YW3-56 inhibited proliferation of a human hepatocellular carcinoma cell line in culture (PMID: 25612620).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4006,
                "therapyName": "YW3-56",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5233,
                    "pubMedId": 25612620,
                    "title": "ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25612620"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6081,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with hepatocellular carcinoma demonstrated a partial response for 44 days when treated with PF-03446962 (PMID: 26655846).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2029,
                "therapyName": "PF-03446962",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5295,
                    "pubMedId": 26655846,
                    "title": "A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26655846"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6195,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NSC156529 inhibited growth of human hepatocellular carcinoma cell lines in culture (PMID: 26294745).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4085,
                "therapyName": "NSC156529",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5386,
                    "pubMedId": 26294745,
                    "title": "A Novel Inhibitor of AKT1-PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26294745"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6207,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, BCORL1 over expression was associated with decreased overall survival and recurrence-free survival in patients with hepatocellular carcinoma (PMID: 26879601), suggesting that this may serve as a future prognostic biomarker.",
            "molecularProfile": {
                "id": 22835,
                "profileName": "BCORL1 over exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5456,
                    "pubMedId": 26879601,
                    "title": "BCORL1 is an independent prognostic marker and contributes to cell migration and invasion in human hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26879601"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6389,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 17-demethoxy-reblastatin inhibited growth and induced apoptosis of human hepatocellular carcinoma cell lines in culture (PMID: 26323360).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4122,
                "therapyName": "17-Demethoxy-reblastatin",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5539,
                    "pubMedId": 26323360,
                    "title": "17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces mitochondria-mediated apoptosis through downregulation of Mcl-1 in human hepatocellular carcinoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26323360"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6390,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human hepatocellular carcinoma cell lines over-expressing MCL1 were resistant to 17-demethoxy-reblastatin induced apoptosis in culture (PMID: 26323360).",
            "molecularProfile": {
                "id": 10008,
                "profileName": "MCL1 over exp"
            },
            "therapy": {
                "id": 4122,
                "therapyName": "17-Demethoxy-reblastatin",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5539,
                    "pubMedId": 26323360,
                    "title": "17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces mitochondria-mediated apoptosis through downregulation of Mcl-1 in human hepatocellular carcinoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26323360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6408,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, 43.8% (7/16) of hepatocellular carcinoma patients treated with a combination of Refametinib (BAY86-9766) and Nexavar (sorafenib) demonstrated stable disease (PMID: 26644411).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2221,
                "therapyName": "Refametinib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5562,
                    "pubMedId": 26644411,
                    "title": "A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26644411"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6509,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) induced apoptosis and decreased growth of hepatocellular carcinoma cell line expressing CCNE1 (cyclin-E1) in culture, which was associated with CCNE1 supression (PMID: 26603262).",
            "molecularProfile": {
                "id": 26180,
                "profileName": "CCNE1 positive"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5671,
                    "pubMedId": 26603262,
                    "title": "Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603262"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6513,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alvocidib (flavopiridol) enhanced the antitumor activity of Nexavar (sorafenib) in hepatocellular carcinoma cells with CCNE1expression in culture and in cell line xenograft models, which was linked to suppression of CCNE1(PMID: 26603262).",
            "molecularProfile": {
                "id": 26180,
                "profileName": "CCNE1 positive"
            },
            "therapy": {
                "id": 4131,
                "therapyName": "Alvocidib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5671,
                    "pubMedId": 26603262,
                    "title": "Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603262"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6523,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, the combination of Resminostat (4SC-201) and Nexavar (sorafenib) demonstrated increased efficacy compared to Resminostat (4SC-201) alone in advanced hepatocellular carcinoma patients, resulting in an improved progression-free survival rate of 62.5% vs. 12.5%, a median time to progression of 4.1 vs. 1.8 months, and an overall survival of 8.0 vs. 6.5 months (PMID: 26952006).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4135,
                "therapyName": "Resminostat + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5684,
                    "pubMedId": 26952006,
                    "title": "Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26952006"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6524,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Domatinostat (4SC-202) inhibited growth and induced apoptosis in hepatocellular carcinoma cell lines in culture (PMID: 26773495).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4136,
                "therapyName": "Domatinostat",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5685,
                    "pubMedId": 26773495,
                    "title": "4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26773495"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6929,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 337 inhibited Met phosphorylation and growth of hepatocellular carcinoma (HCC) cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified HCC patient-derived xenograft models (PMID: 27196749).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5957,
                    "pubMedId": 27196749,
                    "title": "Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196749"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7243,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, the combination of Revlimid (lenalidomide) and Nexavar (sorafenib) was not well-tolerated and did not demonstrate clinical activity in patients with hepatocellular carcinoma, and the study was terminated early due to toxicity (PMID: 27256874).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4426,
                "therapyName": "Lenalidomide + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6255,
                    "pubMedId": 27256874,
                    "title": "Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27256874"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7275,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, inhibition of Parp2 via shRNA enhanced Adriamycin (doxorubicin) induced tumor growth inhibition in cell line xenograft models of hepatocellular carcinoma (PMID: 27300349).",
            "molecularProfile": {
                "id": 24817,
                "profileName": "PARP2 dec exp"
            },
            "therapy": {
                "id": 1009,
                "therapyName": "Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6270,
                    "pubMedId": 27300349,
                    "title": "The clinicopathological significance of miR-149 and PARP-2 in hepatocellular carcinoma and their roles in chemo/radiotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27300349"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7563,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, previously treated hepatocellular carcinoma patients treated with Codrituzumab did not demonstrate a signficantly greater PFS (2.6 vs 1.5 mo) or OS (8.7 vs 10 mo) when compared to placebo (PMID: 27085251).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4518,
                "therapyName": "Codrituzumab",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6422,
                    "pubMedId": 27085251,
                    "title": "Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27085251"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7564,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Brivanib (BMS-540215) treatment used as an adjuvant therapy to Transarterial Chemoembolization (TACE) did not result in a greater overall survival when compared to placebo with TACE in hepatocellular carcinoma patients (PMID: 24996197).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 996,
                "therapyName": "Brivanib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6425,
                    "pubMedId": 24996197,
                    "title": "Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24996197"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7565,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, treatment with Brivanib (BMS-540215) compared to Nexavar (sorafenib) resulted in similar results for overall survival, time to progression, overall response rate, and disease control rate in hepatocellular carcinoma patients (PMID: 23980084).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 996,
                "therapyName": "Brivanib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6427,
                    "pubMedId": 23980084,
                    "title": "Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23980084"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14128,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (REACH-2) that supported FDA approval, Cyramza (ramucirumab) treatment resulted in significantly improved overall survival (8.7 vs 7.3 months, HR=0.71, p=0.0199) and progression-free survival (2.8 vs 1.6 months, HR=0.452, p<0.0001) in hepatocellular carcinoma patients with baseline AFP of 400 ng/ml or higher, and progressed on or were intolerant to Nexavar (sorafenib) (PMID: 30665869; NCT02435433).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 886,
                "therapyName": "Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15091,
                    "pubMedId": 30665869,
                    "title": "Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30665869"
                },
                {
                    "id": 15576,
                    "pubMedId": null,
                    "title": "Cyramza (ramucirumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7612,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (REACH), treatment with Cyramza (ramucirumab) did not result in improved overall survival (OS) compared to placebo (9.2 vs. 7.6 months; HR 0.87 [95% CI 0.72-1.05]; p=0.14) in patients with hepatocellular carcinoma (PMID: 26095784). However, potential benefit on OS (HR 0.80, p=0.06) was observed in patients with a Child-Pugh score of 5 (PMID: 27657674; NCT01140347).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 886,
                "therapyName": "Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6443,
                    "pubMedId": 26095784,
                    "title": "Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26095784"
                },
                {
                    "id": 7780,
                    "pubMedId": 27657674,
                    "title": "Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27657674"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8407,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PRN1371 inhibited proliferation of a hepatocellular carcinoma cell line in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249), which has been demonstrated to have activated Fgfr4 signaling (PMID: 22615798).",
            "molecularProfile": {
                "id": 26312,
                "profileName": "FGFR4 positive"
            },
            "therapy": {
                "id": 3583,
                "therapyName": "PRN1371",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6640,
                    "pubMedId": null,
                    "title": "PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/1249"
                },
                {
                    "id": 6641,
                    "pubMedId": 22615798,
                    "title": "Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22615798"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8713,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Nexavar (sorafenib) and Selumetinib (AZD6244) combination treatment resulted in partial response in 15% (4/27) and stable disease in 48% (13/27) of hepatocellular carcinoma patients (PMID: 27681866).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4801,
                "therapyName": "Selumetinib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6716,
                    "pubMedId": 27681866,
                    "title": "A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27681866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8714,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, the combination treatment of Nexavar (sorafenib) with Tarceva (erlotinib) compared to Nexavar (sorafenib) plus placebo did not demonstrate an improved overall survival and time to progression in patients with hepatocellular carcinoma (PMID: 25547503).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4800,
                "therapyName": "Erlotinib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6715,
                    "pubMedId": 25547503,
                    "title": "SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25547503"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8782,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hepatocellular carcinoma cells with decreased expression of NR0B2 demonstrated decreased CCL2-induced cell migration in culture when treated with DSHN (PMID: 27486225).",
            "molecularProfile": {
                "id": 26435,
                "profileName": "NR0B2 dec exp"
            },
            "therapy": {
                "id": 4809,
                "therapyName": "DSHN",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6747,
                    "pubMedId": 27486225,
                    "title": "A Novel Small Molecule Activator of Nuclear Receptor SHP Inhibits HCC Cell Migration via Suppressing Ccl2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486225"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8984,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with CP-31398 resulted in decreased proliferation, increased apoptosis, and cell-cycle arrest in a hepatocellular carcinoma cell line harboring TP53 Y220C in culture (PMID: 26250460).",
            "molecularProfile": {
                "id": 1043,
                "profileName": "TP53 Y220C"
            },
            "therapy": {
                "id": 3404,
                "therapyName": "CP-31398",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6838,
                    "pubMedId": 26250460,
                    "title": "CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26250460"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8985,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with CP-31398 resulted in decreased proliferation, increased apoptosis, and cell-cycle arrest in a hepatocellular carcinoma cell line harboring TP53 R249S in culture, and inhibited tumor growth in xenograft models (PMID: 26250460).",
            "molecularProfile": {
                "id": 3052,
                "profileName": "TP53 R249S"
            },
            "therapy": {
                "id": 3404,
                "therapyName": "CP-31398",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6838,
                    "pubMedId": 26250460,
                    "title": "CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26250460"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9051,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hepatocellular carcinoma cell lines treated with AZD4547 demonstrated decreased phosphorylation of FGFR1 and FGFR2, reduced colony formation, and evidence of apoptotic activity in culture (PMID: 26351320).",
            "molecularProfile": {
                "id": 26701,
                "profileName": "FGFR1 pos FGFR2 pos"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6889,
                    "pubMedId": 26351320,
                    "title": "Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351320"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9053,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PHA-665752 treatment did not result in decreased colony formation or reduced phosphorylation levels of FGFR1 and FGFR2 in hepatocellular carcinoma cells in culture (PMID: 26351320).",
            "molecularProfile": {
                "id": 26701,
                "profileName": "FGFR1 pos FGFR2 pos"
            },
            "therapy": {
                "id": 2162,
                "therapyName": "PHA-665752",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6889,
                    "pubMedId": 26351320,
                    "title": "Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351320"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9223,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SF1126 inhibited proliferation of hepatocellular carcinoma cell lines in culture, and inhibited tumor growth in hepatocellular carcinoma cell line xenograft models (PMID: 27496136).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 915,
                "therapyName": "SF1126",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7039,
                    "pubMedId": 27496136,
                    "title": "Single Agent and Synergistic Activity of the \"First-in-Class\" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496136"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9224,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of SF1126 and Nexavar (sorafenib) was synergistic or additive in inhibiting proliferation of hepatocellular carcinoma cell lines in culture, and demonstrated increased efficacy in hepatocellular carcinoma cell line xenograft models compared to SF1126 alone (PMID: 23355037).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4956,
                "therapyName": "SF1126 + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7040,
                    "pubMedId": 23355037,
                    "title": "An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23355037"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9237,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) did not inhibit growth of rat hepatocellular carcinoma cells with activated Insr signaling via insulin stimulation in culture (PMID: 27780853).",
            "molecularProfile": {
                "id": 23918,
                "profileName": "INSR positive"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7044,
                    "pubMedId": 27780853,
                    "title": "The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9341,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, addition of Glucophage (metformin) sensitized hepatocellular carcinoma cells to Nexavar (sorafenib) induced apoptosis in culture, resulted in suppression of postoperative intrahepatic recurrence and lung metastasis in cell line xenograft models (PMID: 26957312).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4982,
                "therapyName": "Metformin + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7120,
                    "pubMedId": 26957312,
                    "title": "Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26957312"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9540,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Cometriq (Cabometyx, cabozantinib) and CT-707 resulted in synergism in hepatocellular carcinoma cells, demonstrating increased apoptosis and inhibition of colony formation in culture and decreased tumor weight in xenograft models (PMID: 27638856).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5066,
                "therapyName": "Cabozantinib + CT-707",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7265,
                    "pubMedId": 27638856,
                    "title": "CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27638856"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9541,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PHA-665752 and CT-707 resulted in synergism in hepatocellular carcinoma cells in culture, demonstrating near complete cell death (PMID: 27638856).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5067,
                "therapyName": "CT-707 + PHA-665752",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7265,
                    "pubMedId": 27638856,
                    "title": "CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27638856"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9769,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a hepatocellular carcinoma cell line over expressing FGF19 demonstrated sensitivity to ASP5878, resulting in inhibition of cell proliferation in culture and tumor regression in cell line xenograft models (PMID: 27837028).",
            "molecularProfile": {
                "id": 27058,
                "profileName": "FGF19 over exp"
            },
            "therapy": {
                "id": 3584,
                "therapyName": "ASP5878",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7585,
                    "pubMedId": 27837028,
                    "title": "ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27837028"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9849,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mouse model of hepatocellular carcinoma harboring VEGFA amplification demonstrated a reduction in Hgf levels and decreased cell proliferation when treated with Nexavar (sorafenib) (PMID: 24687604).",
            "molecularProfile": {
                "id": 4727,
                "profileName": "VEGFA amp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7686,
                    "pubMedId": 24687604,
                    "title": "Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24687604"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9848,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Nexavar (sorafenib) treatment in hepatocellular carcinoma patients harboring VEGFA amplification resulted in an improved survival compared to Nexavar (sorafenib) treated patients not harboring VEGFA amplification (PMID: 24687604).",
            "molecularProfile": {
                "id": 4727,
                "profileName": "VEGFA amp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7686,
                    "pubMedId": 24687604,
                    "title": "Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24687604"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9869,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (RESORCE) that supported FDA approval, treatment with Stivarga (regorafenib) following Nexavar (sorafenib) treatment resulted in improved overall survival (10.6 vs 7.8 months, HR=0.63) compared to Nexavar (sorafenib) followed by placebo in patients with hepatocellular carcinoma (PMID: 27932229; NCT01774344).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8404,
                    "pubMedId": 27932229,
                    "title": "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27932229"
                },
                {
                    "id": 15580,
                    "pubMedId": null,
                    "title": "Stivarga (regorafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203085"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10264,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, droxinostat induced apoptosis and reduced growth of hepatocellular carcinoma cell lines in culture (PMID: 26947884).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5452,
                "therapyName": "Droxinostat",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8237,
                    "pubMedId": 26947884,
                    "title": "Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26947884"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10318,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chiauranib (CS2164) inhibited tumor growth in a hepatocellular carcinoma cell line xenograft model (PMID: 28004478).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1998,
                "therapyName": "Chiauranib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8299,
                    "pubMedId": 28004478,
                    "title": "CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28004478"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10381,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, PEGPH20 treatment resulted in median progression free survival of 7.2 months and overall survival of 13.0 months in hepatocellular carcinoma patients with high pretreatment tissue hyaluronan (HA) levels (n = 6), and 3.5 and 5.7 months respectively for patients with low HA levels (n = 11) (PMID: 26813359).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2140,
                "therapyName": "PEGPH20",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8406,
                    "pubMedId": 26813359,
                    "title": "Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26813359"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10389,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, rapamycin (sirolimus) prevented proliferation and colony formation of hepatocellular carcinoma cells with loss of Aim2 expression (PMID: 27167192).",
            "molecularProfile": {
                "id": 13317,
                "profileName": "AIM2 loss"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8410,
                    "pubMedId": 27167192,
                    "title": "Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27167192"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10561,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hepatocellular carcinoma cells over expressing TXN were sensitive to IsoA treatment, demonstrating decreased Txn activity and reduced cell viability in culture, and decreased tumor volume in xenograft models (PMID: 28011619).",
            "molecularProfile": {
                "id": 27620,
                "profileName": "TXN over exp"
            },
            "therapy": {
                "id": 5563,
                "therapyName": "IsoA",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8632,
                    "pubMedId": 28011619,
                    "title": "The Natural Diterpenoid Isoforretin A Inhibits Thioredoxin-1 and Triggers Potent ROS-Mediated Antitumor Effects.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28011619"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10657,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rilutek (riluzole) inhibited growth of hepatocellular cancer cell lines and primary hepatocellular cancer lines in culture (PMID: 27612558).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1047,
                "therapyName": "Riluzole",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8711,
                    "pubMedId": 27612558,
                    "title": "Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells by elevated ROS production.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27612558"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10802,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BLU-554 demonstrated safety and preliminary efficacy, resulting in radiographic partial response in 12.5% (1/8) and stable disease in 12.5% (1/8) of patients with hepatocellular carcinoma, and tumors in both responders were FGF19 positive (European Journal of Cancer, Dec 2016, Vol 69, Suppl 1, S41).",
            "molecularProfile": {
                "id": 21999,
                "profileName": "FGF19 positive"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8833,
                    "pubMedId": null,
                    "title": "First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation",
                    "url": "http://www.sciencedirect.com/science/article/pii/S0959804916327046?via%3Dihub"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11975,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BLU-554 treatment resulted in tumor reduction in 58% (11/19, 1 complete response, 4 partial response, 6 stable disease) of Fgf19-positive hepatocellular carcinoma patients, but only in 15% (4/27, 4 stable disease) of Fgf19-negative patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 365O; NCT02508467).",
            "molecularProfile": {
                "id": 21999,
                "profileName": "FGF19 positive"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9941,
                    "pubMedId": null,
                    "title": "Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC)",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10805,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU9931 inhibited Fgfr4 signaling, resulted in growth inhibition of FGF19-amplified hepatocellular carcinoma cell lines in culture, and tumor regression in cell line xenograft models (PMID: 25776529).",
            "molecularProfile": {
                "id": 13318,
                "profileName": "FGF19 amp"
            },
            "therapy": {
                "id": 2509,
                "therapyName": "BLU9931",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2415,
                    "pubMedId": 25776529,
                    "title": "First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25776529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10806,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU9931 inhibited Fgfr4 function and proliferation in patient-derived hepatocellular carcinoma cell lines with elevated Fgf19 expression, and demonstrated anti-tumor effects in patient-derived xenograft models (PMID: 25776529).",
            "molecularProfile": {
                "id": 27058,
                "profileName": "FGF19 over exp"
            },
            "therapy": {
                "id": 2509,
                "therapyName": "BLU9931",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2415,
                    "pubMedId": 25776529,
                    "title": "First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25776529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10808,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived hepatocellular carcinoma cell lines without detectable Fgf19 expression did not respond to BLU9931 treatment in culture (PMID: 25776529).",
            "molecularProfile": {
                "id": 21998,
                "profileName": "FGF19 negative"
            },
            "therapy": {
                "id": 2509,
                "therapyName": "BLU9931",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2415,
                    "pubMedId": 25776529,
                    "title": "First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25776529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11058,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Foretinib (GSK1363089) demonstrated safety and activity in hepatocellular carcinoma patients, with an overall response rate by mRESCIST of 22.9% (8/35, all partial responses), a disease stabilization rate of 82.9% (29/35), and a median duration of response of 7.6 months (PMID: 27821605; NCT00920192).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9052,
                    "pubMedId": 27821605,
                    "title": "A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27821605"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11183,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Balversa (erdafitinib) inhibited tumor growth in an FGF19-amplified hepatocellular carcinoma cell line xenograft model (PMID: 28341788).",
            "molecularProfile": {
                "id": 13318,
                "profileName": "FGF19 amp"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9140,
                    "pubMedId": 28341788,
                    "title": "Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341788"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11536,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hepatocellular carcinoma cell lines positive for AURKA and AURKB were sensitive to SNS-314 in culture, demonstrating reduced cell proliferation, induced apoptotic activity, and suppression of YAP activity, a result of AURKA and AURKB inhibition, which led to P21 activity (PMID: 28427193).",
            "molecularProfile": {
                "id": 27730,
                "profileName": "AURKA pos AURKB pos"
            },
            "therapy": {
                "id": 918,
                "therapyName": "SNS-314",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9606,
                    "pubMedId": 28427193,
                    "title": "Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28427193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11601,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hepatocellular carcinoma cells with low Smyd3 expression level were not sensitive to BCI-121 in culture (PMID: 25728514).",
            "molecularProfile": {
                "id": 28172,
                "profileName": "SMYD3 dec exp"
            },
            "therapy": {
                "id": 6073,
                "therapyName": "BCI-121",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9659,
                    "pubMedId": 25728514,
                    "title": "A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25728514"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11738,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TRC 105 and Nexavar (sorafenib) combination treatment resulted in an overall response rate of 21% (5/24), median progression-free survival of 3.8 months, and median overall survival of 15.5 months in patients with hepatocellular carcinoma (PMID: 28465443).",
            "molecularProfile": {
                "id": 28203,
                "profileName": "ENG positive"
            },
            "therapy": {
                "id": 2389,
                "therapyName": "Carotuximab + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9755,
                    "pubMedId": 28465443,
                    "title": "Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28465443"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11816,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with RU-A1 in hepatocellular carcinoma cells resulted in decreased cell survival and migration in culture and reduced tumor growth and improved survival in cell line xenograft zebrafish models (PMID: 28589491).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6165,
                "therapyName": "RU-A1",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9860,
                    "pubMedId": 28589491,
                    "title": "Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28589491"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11817,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RU-A1 enhanced the sensitivity of Adrucil (fluorouracil) treatment in hepatocellular carcinoma cells, demonstrating greater decreased cell survival and inhibition of colony formation in culture compared to treatment with either agent alone (PMID: 28589491).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6167,
                "therapyName": "Fluorouracil + RU-A1",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9860,
                    "pubMedId": 28589491,
                    "title": "Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28589491"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11976,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BLU-554 treatment resulted in tumor reduction in 58% (11/19, 1 complete response, 4 partial response, 6 stable disease) of Fgf19-positive hepatocellular carcinoma patients, but only in 15% (4/27, 4 stable disease) of Fgf19-negative patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 365O; NCT02508467).",
            "molecularProfile": {
                "id": 21998,
                "profileName": "FGF19 negative"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9941,
                    "pubMedId": null,
                    "title": "Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC)",
                    "url": "http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12079,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial (CheckMate 040) that supproted FDA approval, Opdivo (nivolumab) treatment resulted in complete response in 1% (3/214), partial response in 18% (39/214), and stable disease in 45% (96/214) of hepatocellular carcinoma patients (PMID: 28434648; NCT01658878).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10013,
                    "pubMedId": 28434648,
                    "title": "Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28434648"
                },
                {
                    "id": 15569,
                    "pubMedId": null,
                    "title": "Opdivo (nivolumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12078,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial that supported FDA approval, Opdivo (nivolumab) treatment resulted in complete response in 1.9% (3/154) and partial response in 12.3% (19/154) of hepatocellular carcinoma patients who progressed on or were intolerant to Nexavar (sorafenib) (J Clin Oncol 35, 2017 (suppl; abstr 4013); NCT01658878).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10012,
                    "pubMedId": null,
                    "title": "Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.",
                    "url": "http://meetinglibrary.asco.org/record/152902/abstract"
                },
                {
                    "id": 15569,
                    "pubMedId": null,
                    "title": "Opdivo (nivolumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12096,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, FGF401 treatment resulted in an overall response rate of 8% (4/53) and stable disease in 53% (28/53) of hepatocellular carcinoma patients with Fgfr4/Klb expression (Cancer Res 2017;77(13 Suppl):Abstract nr CT106; NCT02325739).",
            "molecularProfile": {
                "id": 26312,
                "profileName": "FGFR4 positive"
            },
            "therapy": {
                "id": 2031,
                "therapyName": "FGF401",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10038,
                    "pubMedId": null,
                    "title": "Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/CT106.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12097,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, FGF401 treatment resulted in an overall response rate of 8% (4/53) and stable disease in 53% (28/53) of hepatocellular carcinoma patients with Fgfr4/Klb expression (Cancer Res 2017;77(13 Suppl):Abstract nr CT106; NCT02325739).",
            "molecularProfile": {
                "id": 27807,
                "profileName": "KLB positive"
            },
            "therapy": {
                "id": 2031,
                "therapyName": "FGF401",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10038,
                    "pubMedId": null,
                    "title": "Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/CT106.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12256,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CEBPA-51 treatment resulted in induced expression of CEBPA mRNA and inhibited proliferation of hepatocellular carcinoma cells in culture (PMID: 28882451).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6396,
                "therapyName": "CEBPA-51",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10217,
                    "pubMedId": 28882451,
                    "title": "Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28882451"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15155,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CEBPA-51 treatment resulted in increased Cebpa expression in WBC, stable disease over 4 months in 40% (4/10) of patients with hepatocellular carcinoma, with 1 patient achieved partial response for 18 months (J Clin Oncol, 36(no. 15_suppl), May 2018, 2509-2509; NCT02716012).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6396,
                "therapyName": "CEBPA-51",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 12750,
                    "pubMedId": null,
                    "title": "Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-? in patients with advanced liver cancer.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2509"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12619,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MO-I-1100 inhibited Notch signaling and growth of tumors in xenograft and cell line models of hepatocellular carcinoma with Asph overexpression (PMID: 24954865).",
            "molecularProfile": {
                "id": 28790,
                "profileName": "ASPH over exp"
            },
            "therapy": {
                "id": 6544,
                "therapyName": "MO-I-1100",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10500,
                    "pubMedId": 24954865,
                    "title": "A cell-surface \u03b2-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24954865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12733,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGF19 overexpression was associated with sensitivity to H3B-6527 in hepatocellular carcinoma cell lines in culture and in xenograft models, and in hepatocellular carcinoma patient-derived xenograft (PDX) models (PMID: 29247039).",
            "molecularProfile": {
                "id": 27058,
                "profileName": "FGF19 over exp"
            },
            "therapy": {
                "id": 6610,
                "therapyName": "H3B-6527",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10667,
                    "pubMedId": 29247039,
                    "title": "H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247039"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12734,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, H3B-6527 inhibited FGFR4 pathway signaling and proliferation and induced apoptosis in an FGF19-amplified hepatocellular carcinoma cell line in culture, and inhibited tumor growth in xenograft models (PMID: 29247039).",
            "molecularProfile": {
                "id": 13318,
                "profileName": "FGF19 amp"
            },
            "therapy": {
                "id": 6610,
                "therapyName": "H3B-6527",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10667,
                    "pubMedId": 29247039,
                    "title": "H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247039"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12736,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of H3B-6527 and Ibrance (palbociclib) resulted in tumor regression and enhanced tumor growth inhibition compared to H3B-6527 alone in cell line xenograft models of hepatocellular carcinoma with overexpression of FGF19 (PMID: 29247039).",
            "molecularProfile": {
                "id": 27058,
                "profileName": "FGF19 over exp"
            },
            "therapy": {
                "id": 6611,
                "therapyName": "H3B-6527 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10667,
                    "pubMedId": 29247039,
                    "title": "H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247039"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12825,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PRN1371 inhibited proliferation of FGF19 amplified hepatocellular carcinoma cell lines in culture (PMID: 28978721).",
            "molecularProfile": {
                "id": 13318,
                "profileName": "FGF19 amp"
            },
            "therapy": {
                "id": 3583,
                "therapyName": "PRN1371",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10753,
                    "pubMedId": 28978721,
                    "title": "The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28978721"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12865,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with SGI-1027 reduced proliferation of a rat hepatoma cell line in culture in culture (PMID: 19417133).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1532,
                "therapyName": "SGI-1027",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 823,
                    "pubMedId": 19417133,
                    "title": "A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19417133"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13556,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of Bmp4 resulted in resistance to oxaliplatin in hepatocellular carcinoma cell lines and xenografts (PMID: 28987388).",
            "molecularProfile": {
                "id": 28176,
                "profileName": "BMP4 over exp"
            },
            "therapy": {
                "id": 1104,
                "therapyName": "Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11182,
                    "pubMedId": 28987388,
                    "title": "BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling\u00a0in\u00a0hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28987388"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13557,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KU-0063794 inhibited cell survival and reduced colony formation of hepatocellular carcinoma cells in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26278819).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2228,
                "therapyName": "KU-0063794",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11184,
                    "pubMedId": 26278819,
                    "title": "Autophagy inhibition sensitizes KU-0063794-mediated anti-HepG2 hepatocellular carcinoma cell activity in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26278819"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13586,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hepatocellular carcinoma patient-derived xenograft (PDX) models overexpressing MET were sensitive to SCC244, demonstrating a complete response in one and partial response in eleven (PMID: 29237805).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 6844,
                "therapyName": "SCC244",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11200,
                    "pubMedId": 29237805,
                    "title": "Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29237805"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13872,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Camrelizumab (SHR-1210) demonstrated safety and preliminary anti-tumor activity, resulted in partial response in 33.3% (1/3) of patients with hepatocellular carcinoma (J Clin Onc. 2017 35:15_suppl, e15572-e15572; NCT02742935).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6137,
                "therapyName": "Camrelizumab",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9759,
                    "pubMedId": null,
                    "title": "Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e15572"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13990,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GNS561 inhibited growth of hepatocellular carcinoma cell lines in culture, and tumor growth in patient-derive xenograft (PDX) models (Cancer Res 2017;77(13 Suppl):Abstract nr 5124).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6985,
                "therapyName": "GNS561",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11404,
                    "pubMedId": null,
                    "title": "GNS561 a new quinoline derivative inhibits the growth of hepatocellular carcinoma in a cirrhotic rat and human PDX orthotopic mouse models",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5124"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14479,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MINT1526A in combination with Avastin (bevacizumab) resulted in durable minor radiographic responses in 2 patients with hepatocellular carcinoma (PMID: 29905898).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7095,
                "therapyName": "Bevacizumab + MINT1526A",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11646,
                    "pubMedId": 29905898,
                    "title": "Phase I study of the anti-\u03b15\u03b21 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29905898"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14977,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, INCB062079 reduced tumor cell growth in patient-derived xenograft models from patients with hepatocellular carcinoma and FGF19 amplification (AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1234).",
            "molecularProfile": {
                "id": 13318,
                "profileName": "FGF19 amp"
            },
            "therapy": {
                "id": 5832,
                "therapyName": "INCB062079",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11917,
                    "pubMedId": null,
                    "title": "The novel FGFR4-selective inhibitor INCB062079 is efficacious in models of hepatocellular carcinoma harboring FGF19 amplification",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/1234.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15077,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Refametinib (BAY86-9766) and Nexavar (sorafenib) combination treatment resulted in an objective response rate of 6.3% (1/16), a disease control rate of 43.8% (7/16), an overall survival of 12.7 months, and a progression-free survival of 1.5 months in patients unresectable or metastatic hepatocellular carcinoma harboring RAS (NRAS and KRAS) mutations (PMID: 29950351; NCT01915602).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 2221,
                "therapyName": "Refametinib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12624,
                    "pubMedId": 29950351,
                    "title": "Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29950351"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15139,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In a meta analysis, overexpression of Gpc3 is associated with poor prognosis in patients with hepatocellular carcinoma (PMID: 29901640, PMID: 28621802, PMID: 29369198).",
            "molecularProfile": {
                "id": 30787,
                "profileName": "GPC3 over exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 12683,
                    "pubMedId": 29901640,
                    "title": "Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29901640"
                },
                {
                    "id": 12684,
                    "pubMedId": 28621802,
                    "title": "Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28621802"
                },
                {
                    "id": 12685,
                    "pubMedId": 29369198,
                    "title": "Prognostic significance of glypican-3 expression in hepatocellular carcinoma: A meta-analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29369198"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15182,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (KEYNOTE-224) that suported FDA approval, Keytruda (pembrolizumab) treatment resulted in an overall response rate of 16.3% (17/104, 1 complete response, 16 partial response), and stable disease in 45.2% (47/104) of hepatocellular carcinoma patients previously treated with sorafenib, with a median progression-free survival of 4.8 months (J Clin Oncol, 36 (4_suppl), February 2018, 209-209; NCT02702414).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 12803,
                    "pubMedId": null,
                    "title": "KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.209"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15704,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CELESTIAL) that supported FDA approval, Cabometyx (cabozantinib) significantly improved overall survival (10.2 vs 8.0 months, HR=0.76, p=0.005) and progression-free survival (5.2 vs 1.9 months, HR=0.44, p<0.001) compared to placebo in patients with previously treated advanced hepatocellular carcinoma (PMID: 29972759; NCT01908426).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13586,
                    "pubMedId": 29972759,
                    "title": "Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29972759"
                },
                {
                    "id": 15613,
                    "pubMedId": null,
                    "title": "Cabometyx (cabozantinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208692"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15927,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, second-line treatment with Tivantinib (ARQ197) did not result in improved overall survival over placebo in hepatocellular carcinoma patients with high MET expression (PMID: 29625879; NCT01755767).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 636,
                "therapyName": "Tivantinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14014,
                    "pubMedId": 29625879,
                    "title": "Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29625879"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15966,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, combined Camrelizumab (SHR-1210) and Apatinib (YN968D1) treatment resulted in an overall response rate of 50% (8/16), a disease control rate of 93.8% (15/16, stable disease or better), a median progression-free survival (PFS) of 5.8 months, and a 9-month PFS rate of 41.0% in evaluable patients with advanced hepatocellular carcinoma (PMID: 30348638; NCT02942329).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7840,
                "therapyName": "Apatinib + Camrelizumab",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14095,
                    "pubMedId": 30348638,
                    "title": "Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30348638"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16241,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nexavar (sorafenib) treatment of patients with hepatocellular carcinoma harboring Mtor pathway mutations in PIK3CA, PTEN, TSC2, or TSC1 (n=12), resulted in a lower disease control rate (8.3% vs. 40.2%), shorter progression-free survival (1.9 months vs. 5.3 months) and shorter overall survival (10.4 months vs. 17.9 months) compared to patients without mutations in this pathway (n=67) (PMID: 30373752; NCT01775072).",
            "molecularProfile": {
                "id": 429,
                "profileName": "PIK3CA mutant"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16242,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nexavar (sorafenib) treatment of patients with hepatocellular carcinoma harboring Mtor pathway mutations in PIK3CA, PTEN, TSC2, or TSC1 (n=12), resulted in a lower disease control rate (8.3% vs. 40.2%), shorter progression-free survival (1.9 months vs. 5.3 months) and shorter overall survival (10.4 months vs. 17.9 months) compared to patients without mutations in this pathway (n=67) (PMID: 30373752; NCT01775072).",
            "molecularProfile": {
                "id": 1213,
                "profileName": "PTEN mutant"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16244,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nexavar (sorafenib) treatment of patients with hepatocellular carcinoma harboring Mtor pathway mutations in PIK3CA, PTEN, TSC2, or TSC1 (n=12), resulted in a lower disease control rate (8.3% vs. 40.2%), shorter progression-free survival (1.9 months vs. 5.3 months) and shorter overall survival (10.4 months vs. 17.9 months) compared to patients without mutations in this pathway (n=67) (PMID: 30373752; NCT01775072).",
            "molecularProfile": {
                "id": 1245,
                "profileName": "TSC2 mutant"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16245,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nexavar (sorafenib) treatment of patients with hepatocellular carcinoma harboring Mtor pathway mutations in PIK3CA, PTEN, TSC2, or TSC1 (n=12), resulted in a lower disease control rate (8.3% vs. 40.2%), shorter progression-free survival (1.9 months vs. 5.3 months) and shorter overall survival (10.4 months vs. 17.9 months) compared to patients without mutations in this pathway (n=67) (PMID: 30373752; NCT01775072).",
            "molecularProfile": {
                "id": 1244,
                "profileName": "TSC1 mutant"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16249,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment with immune checkpoint antibodies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy or combinations of anti-PD-1 with anti-CTLA-4, anti-LAG3, or anti-KIR, was less effective in patients with Wnt pathway mutations in CTNNB1 or AXIN1 compared to patients without mutations in this pathway, with 0% (0/10) vs. 53% (9/17) achieving disease control, respectively, and shorter progression-free survival (2.0 months vs. 7.4 months) (PMID: 30373752; NCT01775072).",
            "molecularProfile": {
                "id": 3638,
                "profileName": "CTNNB1 act mut"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16250,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment with immune checkpoint antibodies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy or combinations of anti-PD-1 with anti-CTLA-4, anti-LAG3, or anti-KIR, was less effective in patients with Wnt pathway mutations in CTNNB1 or AXIN1 compared to patients without mutations in this pathway, with 0% (0/10) vs. 53% (9/17) achieving disease control, respectively, and shorter progression-free survival (2.0 months vs. 7.4 months) (PMID: 30373752; NCT01775072).",
            "molecularProfile": {
                "id": 12071,
                "profileName": "AXIN1 inact mut"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16252,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment with immune checkpoint antibodies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy or combinations of anti-PD-1 with anti-CTLA-4, anti-LAG3, or anti-KIR, was less effective in patients with Wnt pathway mutations in CTNNB1 or AXIN1 compared to patients without mutations in this pathway, with 0% (0/10) vs. 53% (9/17) achieving disease control, respectively, and shorter progression-free survival (2.0 months vs. 7.4 months) (PMID: 30373752; NCT01775072).",
            "molecularProfile": {
                "id": 3638,
                "profileName": "CTNNB1 act mut"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16253,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment with immune checkpoint antibodies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy or combinations of anti-PD-1 with anti-CTLA-4, anti-LAG3, or anti-KIR, was less effective in patients with Wnt pathway mutations in CTNNB1 or AXIN1 compared to patients without mutations in this pathway, with 0% (0/10) vs. 53% (9/17) achieving disease control, respectively, and shorter progression-free survival (2.0 months vs. 7.4 months) (PMID: 30373752; NCT01775072).",
            "molecularProfile": {
                "id": 12071,
                "profileName": "AXIN1 inact mut"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16255,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment with immune checkpoint antibodies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy or combinations of anti-PD-1 with anti-CTLA-4, anti-LAG3, or anti-KIR, was less effective in patients with Wnt pathway mutations in CTNNB1 or AXIN1 compared to patients without mutations in this pathway, with 0% (0/10) vs. 53% (9/17) achieving disease control, respectively, and shorter progression-free survival (2.0 months vs. 7.4 months) (PMID: 30373752; NCT01775072).",
            "molecularProfile": {
                "id": 3638,
                "profileName": "CTNNB1 act mut"
            },
            "therapy": {
                "id": 5489,
                "therapyName": "unspecified CTLA4 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16257,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment with immune checkpoint antibodies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy or combinations of anti-PD-1 with anti-CTLA-4, anti-LAG3, or anti-KIR, was less effective in patients with Wnt pathway mutations in CTNNB1 or AXIN1 compared to patients without mutations in this pathway, with 0% (0/10) vs. 53% (9/17) achieving disease control, respectively, and shorter progression-free survival (2.0 months vs. 7.4 months) (PMID: 30373752; NCT01775072).",
            "molecularProfile": {
                "id": 12071,
                "profileName": "AXIN1 inact mut"
            },
            "therapy": {
                "id": 5489,
                "therapyName": "unspecified CTLA4 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16258,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment with immune checkpoint antibodies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy or combinations of anti-PD-1 with anti-CTLA-4, anti-LAG3, or anti-KIR, was less effective in patients with Wnt pathway mutations in CTNNB1 or AXIN1 compared to patients without mutations in this pathway, with 0% (0/10) vs. 53% (9/17) achieving disease control, respectively, and shorter progression-free survival (2.0 months vs. 7.4 months) (PMID: 30373752; NCT01775072).",
            "molecularProfile": {
                "id": 3638,
                "profileName": "CTNNB1 act mut"
            },
            "therapy": {
                "id": 6804,
                "therapyName": "unspecified CTLA4 antibody + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16259,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment with immune checkpoint antibodies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy or combinations of anti-PD-1 with anti-CTLA-4, anti-LAG3, or anti-KIR, was less effective in patients with Wnt pathway mutations in CTNNB1 or AXIN1 compared to patients without mutations in this pathway, with 0% (0/10) vs. 53% (9/17) achieving disease control, respectively, and shorter progression-free survival (2.0 months vs. 7.4 months) (PMID: 30373752; NCT01775072).",
            "molecularProfile": {
                "id": 12071,
                "profileName": "AXIN1 inact mut"
            },
            "therapy": {
                "id": 6804,
                "therapyName": "unspecified CTLA4 antibody + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16503,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xenical (orlistat) inhibited lipid metabolism and induced cell death in hepatocellular carcinoma cells in culture (PMID: 30667213).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8071,
                "therapyName": "Orlistat",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13892,
                    "pubMedId": 30667213,
                    "title": "Orlistat Displays Antitumor Activity and Enhances the Efficacy of Paclitaxel in Human Hepatoma Hep3B Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30667213"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16504,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xenical (orlistat) and Taxol (paclitaxel) synergistically inhibited growth and induced apoptosis in hepatocellular carcinoma cells in culture (PMID: 30667213).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8072,
                "therapyName": "Orlistat + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13892,
                    "pubMedId": 30667213,
                    "title": "Orlistat Displays Antitumor Activity and Enhances the Efficacy of Paclitaxel in Human Hepatoma Hep3B Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30667213"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16554,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Avasimibe inhibited tumor growth in hepatocellular carcinoma patient-derived xenograft (PDX) models with high SOAT1 expression (PMID: 30814741).",
            "molecularProfile": {
                "id": 31663,
                "profileName": "SOAT1 over exp"
            },
            "therapy": {
                "id": 8102,
                "therapyName": "Avasimibe",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14617,
                    "pubMedId": 30814741,
                    "title": "Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30814741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16840,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TPX-0022 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of hepatocellular carcinoma harboring MET amplification (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1321).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 8205,
                "therapyName": "TPX-0022",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14951,
                    "pubMedId": null,
                    "title": "TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC for treatment of cancers with abnormal HGF/MET signaling.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18026,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, addition of Dalantercept (ACE-041) to Nexavar (sorafenib) was well tolerated, but did not improve the efficacy of Nexavar (sorafenib) in patients with advanced hepatocellular carcinoma, with overall survival ranged from 1.9 to 23.3 months and stable disease as best overall response in 53.3% (11/21) of the patients (PMID: 30352941; NCT02024087).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2364,
                "therapyName": "Dalantercept + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15941,
                    "pubMedId": 30352941,
                    "title": "A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30352941"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18493,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, Adriamycin (doxorubicin) treatment combined with knockdown of endogenous Smc1a via shRNA resulted in reduced viability of hepatocellular carcinoma cells expressing SMC1A in culture (PMID: 29988990).",
            "molecularProfile": {
                "id": 35179,
                "profileName": "SMC1A positive"
            },
            "therapy": {
                "id": 1009,
                "therapyName": "Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16115,
                    "pubMedId": 29988990,
                    "title": "Phosphorylation of SMC1A promotes hepatocellular carcinoma cell proliferation and migration.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29988990"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18539,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, Emibetuzumab (LY2875358) and Cyramza (ramucirumab) combination treatment resulted in an objective response rate of 6.7% (3/45) and a disease control rate of 60% (27/45) in patients with hepatocellular carcinoma, with a median progression-free survival (mPFS) of 5.4 months, patients with MET expression of 2+ or above in over 50% of tumor cells (n=19) demonstrated improved mPFS (8.1 vs 2.8 mo, HR=0.22) compared to patients below the cut-off (n=14) (PMID: 31142504; NCT02082210).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 1387,
                "therapyName": "Emibetuzumab + Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16219,
                    "pubMedId": 31142504,
                    "title": "A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31142504"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19380,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Poteligeo (mogamulizumab-kpkc) and Opdivo (nivolumab) combination treatment demonstrated acceptable safety, resulted in an objective response rate of 27% (4/15, 4 partial responses) and a disease control rate of 67% (10/15) in immunotherapy-naive patients with advanced or metastatic hepatocellular carcinoma, response occurred regardless of PD-L1, CCR4, CD8 expression levels and tumor mutational burden (PMID: 31455681; NCT02476123).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3843,
                "therapyName": "Mogamulizumab + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16935,
                    "pubMedId": 31455681,
                    "title": "A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31455681"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19457,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGF401 inhibited proliferation of FGF19, KLB, and FGFR4-positive hepatocellular carcinoma cell lines in culture, and inhibited tumor growth and induced tumor stasis and regression in cell line and patient-derived xenograft (PDX) models of hepatocellular carcinoma (PMID: 31409633).",
            "molecularProfile": {
                "id": 34158,
                "profileName": "FGF19 pos FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 2031,
                "therapyName": "FGF401",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17101,
                    "pubMedId": 31409633,
                    "title": "FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31409633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19461,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) did not significantly inhibit tumor growth in a cell line xenograft model of FGF19, KLB, and FGFR4-positive hepatocellular carcinoma compared to FGF401 treatment (PMID: 31409633).",
            "molecularProfile": {
                "id": 34158,
                "profileName": "FGF19 pos FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 17101,
                    "pubMedId": 31409633,
                    "title": "FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31409633"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19587,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with hepatocellular carcinoma overexpressing FGF19 was sensitive to treatment with Fisogatinib (BLU-554), demonstrating a partial response with a 44% decrease in tumor size after 16 weeks (PMID: 31575540).",
            "molecularProfile": {
                "id": 27058,
                "profileName": "FGF19 over exp"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19588,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with hepatocellular carcinoma overexpressing FGF19 initially responded to Fisogatinib (BLU-554) treatment, but progressed at week 32 and was found via circulating tumor DNA testing to have acquired FGFR4 V550M, FGFR4 V550L, and FGFR4 C552R (PMID: 31575540).",
            "molecularProfile": {
                "id": 34258,
                "profileName": "FGF19 over exp FGFR4 V550L FGFR4 V550M FGFR4 C552R"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19589,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with hepatocellular carcinoma and overexpression of FGF19 initially experienced stable disease and a 15% decrease in tumor size when treated with Fisogatinib (BLU-554), but then progressed and was found via circulating tumor DNA to have acquired FGFR4 V550M (PMID: 31575540).",
            "molecularProfile": {
                "id": 34266,
                "profileName": "FGF19 over exp FGFR4 V550M"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19598,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a hepatocellular carcinoma cell line xenograft model with FGF19 amplification, FGFR4 and KLB expression, and FGFR4 V550L demonstrated resistance to treatment with Fisogatinib (BLU-554) (PMID: 31575540).",
            "molecularProfile": {
                "id": 34275,
                "profileName": "FGF19 amp FGFR4 V550L FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19600,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a hepatocellular carcinoma cell line xenograft model with FGF19 amplification and FGFR4 and KLB expression demonstrated resistance to treatment with Fisogatinib (BLU-554) and was subsequently found to have acquired FGFR4 C552F (PMID: 31575540).",
            "molecularProfile": {
                "id": 34276,
                "profileName": "FGF19 amp FGFR4 C552F FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19601,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a hepatocellular carcinoma cell line xenograft model with FGF19 amplification and FGFR4 and KLB expression demonstrated resistance to treatment with Fisogatinib (BLU-554) and was subsequently found to have acquired FGFR4 V550M (PMID: 31575540).",
            "molecularProfile": {
                "id": 34277,
                "profileName": "FGF19 amp FGFR4 V550M FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19609,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a hepatocellular carcinoma cell line xenograft model with FGF19 amplification, FGFR4 and KLB expression, and FGFR4 V550M demonstrated delayed tumor growth when treated with LY2874455 (PMID: 31575540).",
            "molecularProfile": {
                "id": 34277,
                "profileName": "FGF19 amp FGFR4 V550M FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 2032,
                "therapyName": "LY2874455",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20168,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with SLMP53-2 induced cell-cycle arrest and apoptosis and inhibited growth, and resulted in restored Tp53 transcriptional activity in a hepatocellular carcinoma cell line harboring TP53 Y220C in culture, and inhibited tumor growth in xenograft models (PMID: 31405179).",
            "molecularProfile": {
                "id": 1043,
                "profileName": "TP53 Y220C"
            },
            "therapy": {
                "id": 9281,
                "therapyName": "SLMP53-2",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17718,
                    "pubMedId": 31405179,
                    "title": "SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31405179"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20169,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of SLMP53-2 and Nexavar (sorafenib) inhibited growth of a hepatocellular carcinoma cell line harboring TP53 Y220C in culture, and resulted in increased inhibition compared to Nexavar (sorafenib) alone (PMID: 31405179).",
            "molecularProfile": {
                "id": 1043,
                "profileName": "TP53 Y220C"
            },
            "therapy": {
                "id": 9282,
                "therapyName": "SLMP53-2 + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17718,
                    "pubMedId": 31405179,
                    "title": "SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31405179"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20175,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vitrakvi (larotrectinib) is included in guidelines as subsequent-line therapy for patients with hepatocellular carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2904,
                "profileName": "NTRK1 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20176,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vitrakvi (larotrectinib) is included in guidelines as subsequent-line therapy for patients with hepatocellular carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2908,
                "profileName": "NTRK2 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20177,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vitrakvi (larotrectinib) is included in guidelines as subsequent-line therapy for patients with hepatocellular carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2909,
                "profileName": "NTRK3 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20178,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rozlytrek (entrectinib) is included in guidelines as subsequent-line therapy for patients with hepatocellular carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2904,
                "profileName": "NTRK1 fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20179,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rozlytrek (entrectinib) is included in guidelines as subsequent-line therapy for patients with hepatocellular carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2908,
                "profileName": "NTRK2 fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20180,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rozlytrek (entrectinib) is included in guidelines as subsequent-line therapy for patients with hepatocellular carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2909,
                "profileName": "NTRK3 fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20275,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) treatment resulted in cell cycle arrest, DNA damage, and apoptosis in hepatocellular carcinoma cell lines with ATRX gene knocked out via CRISPR-Cas9 in culture, and inhibited tumor growth in cell line xenograft models (PMID: 31551363).",
            "molecularProfile": {
                "id": 35009,
                "profileName": "ATRX del"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17792,
                    "pubMedId": 31551363,
                    "title": "Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX-Mutant Cancers to WEE1 Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31551363"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20395,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI-503 treatment inhibited migration and growth of a MEN1- and KMT2A-positive hepatocellular carcinoma cell line in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 29142068).",
            "molecularProfile": {
                "id": 35164,
                "profileName": "KMT2A pos MEN1 pos"
            },
            "therapy": {
                "id": 6006,
                "therapyName": "MI-503",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17829,
                    "pubMedId": 29142068,
                    "title": "Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29142068"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20400,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI-503 and Nexavar (sorafenib) treatment synergistically inhibited growth of a MEN1 and KMT2A-positive hepatocellular carcinoma cell line in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 29142068).",
            "molecularProfile": {
                "id": 35164,
                "profileName": "KMT2A pos MEN1 pos"
            },
            "therapy": {
                "id": 9343,
                "therapyName": "MI-503 + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17829,
                    "pubMedId": 29142068,
                    "title": "Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29142068"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20435,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hepatocellular carcinoma cell lines expressing FGF19, FGFR4, and KLB demonstrated sensitivity to treatment with Fisogatinib (BLU-554) in culture (PMID: 31409633).",
            "molecularProfile": {
                "id": 34158,
                "profileName": "FGF19 pos FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17101,
                    "pubMedId": 31409633,
                    "title": "FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31409633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20436,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hepatocellular carcinoma cell lines expressing FGF19, FGFR4, and KLB demonstrated sensitivity to treatment with H3B-6527 in culture (PMID: 31409633).",
            "molecularProfile": {
                "id": 34158,
                "profileName": "FGF19 pos FGFR4 pos KLB pos"
            },
            "therapy": {
                "id": 6610,
                "therapyName": "H3B-6527",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17101,
                    "pubMedId": 31409633,
                    "title": "FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31409633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20912,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I (CheckMate 040) trial that supported FDA approval, combination of Opdivo (nivolumab) and Yervoy (ipilimumab) was well tolerated, resulted in an objective response rate of 32% (16/50, 4 complete response, 12 partial response) with a median duration of response of 17 months in patients with hepatocellular carcinoma previously treated with Nexavar (sorafenib) (J Clin Oncol 37, no. 15_suppl (May 20, 2019) 4012-4012; NCT01658878).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1627,
                "therapyName": "Ipilimumab + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15569,
                    "pubMedId": null,
                    "title": "Opdivo (nivolumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554"
                },
                {
                    "id": 15570,
                    "pubMedId": null,
                    "title": "Yervoy (ipilimumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377"
                },
                {
                    "id": 18118,
                    "pubMedId": null,
                    "title": "Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4012"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20997,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a hepatocellular carcinoma patient harboring TSC2 D1598fs and TSC2 D1690fs achieved stable disease following treatment with Afinitor (everolimus) (PMID: 30373752).",
            "molecularProfile": {
                "id": 35485,
                "profileName": "TSC2 D1598fs TSC2 D1690fs"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20998,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a hepatocellular carcinoma patient harboring TSC2 E96* achieved stable disease following treatment with Afinitor (everolimus) (PMID: 30373752).",
            "molecularProfile": {
                "id": 35483,
                "profileName": "TSC2 E96*"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20999,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a hepatocellular carcinoma patient harboring TSC1 R98* achieved stable disease following treatment with Afinitor (everolimus) (PMID: 30373752).",
            "molecularProfile": {
                "id": 35484,
                "profileName": "TSC1 R98*"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14385,
                    "pubMedId": 30373752,
                    "title": "Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30373752"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21061,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, CIC S1595P was identified in a patient with hepatocellular carcinoma who developed resistance to Nexavar (sorafenib), and was retained in the cell line established from his tumor, which was resistant to Nexavar (sorafenib) in culture (PMID: 32169577).",
            "molecularProfile": {
                "id": 919,
                "profileName": "CIC S1595P"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18320,
                    "pubMedId": 32169577,
                    "title": "Inactivation of transcriptional repressor Capicua confers sorafenib-resistance in human hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32169577"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21062,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased CIC expression via siRNA knockdown in hepatocellular cells resulted in activation of MAPK signaling and decreased response to Nexavar (sorafenib), and decreased expression of Cic and activation of MAPK signaling were identified in hepatocellular carcinoma cell lines acquired resistance to Nexavar (sorafenib) in culture (PMID: 32169577).",
            "molecularProfile": {
                "id": 35525,
                "profileName": "CIC dec exp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18320,
                    "pubMedId": 32169577,
                    "title": "Inactivation of transcriptional repressor Capicua confers sorafenib-resistance in human hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32169577"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21064,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Stivarga (regorafenib) inhibited MAPK signaling and viability of a hepatocellular carcinoma cell line that acquired Nexavar (sorafenib) resistance with decreased Cic expression in culture, and inhibited tumor growth in xenograft models (PMID: 32169577).",
            "molecularProfile": {
                "id": 919,
                "profileName": "CIC S1595P"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18320,
                    "pubMedId": 32169577,
                    "title": "Inactivation of transcriptional repressor Capicua confers sorafenib-resistance in human hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32169577"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21063,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Stivarga (regorafenib) inhibited MAPK signaling and viability of a patient-derived Nexavar (sorafenib)-resistant hepatocellular carcinoma cell line harboring CIC S1595P in culture, and inhibited tumor growth in xenograft models (PMID: 32169577).",
            "molecularProfile": {
                "id": 919,
                "profileName": "CIC S1595P"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18320,
                    "pubMedId": 32169577,
                    "title": "Inactivation of transcriptional repressor Capicua confers sorafenib-resistance in human hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32169577"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21066,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, high pre-treatment Cic expression level correlated with superior overall survival (p=0.021) in patients with hepatocellular carcinoma compared to patients with low Cic expression (PMID: 32169577).",
            "molecularProfile": {
                "id": 35526,
                "profileName": "CIC over exp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18320,
                    "pubMedId": 32169577,
                    "title": "Inactivation of transcriptional repressor Capicua confers sorafenib-resistance in human hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32169577"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00986661",
            "title": "A Study to Assess PV-10 Chemoablation of Cancer of the Liver",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 879,
                    "therapyName": "PV-10",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01015833",
            "title": "Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01075113",
            "title": "Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2356,
                    "therapyName": "Sorafenib + Vorinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01141478",
            "title": "Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01174121",
            "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01177397",
            "title": "Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 693,
                    "therapyName": "CC-223",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01246986",
            "title": "A Study of LY2157299 in Participants With Hepatocellular Carcinoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2421,
                    "therapyName": "Galunisertib + Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 2409,
                    "therapyName": "Galunisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01306058",
            "title": "Sorafenib and TRC105 in Hepatocellular Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2389,
                    "therapyName": "Carotuximab + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01356628",
            "title": "A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01421524",
            "title": "Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2358,
                    "therapyName": "CC-122",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01556490",
            "title": "Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT01567930",
            "title": "Temsirolimus as Second-line Therapy in HCC",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01624285",
            "title": "Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01628640",
            "title": "Viral Therapy in Treating Patient With Liver Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2423,
                    "therapyName": "VSV-IFN-beta",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01642342",
            "title": "Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3013,
                    "therapyName": "sEphB4-HSA",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01655693",
            "title": "Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (ReLive)",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01658878",
            "title": "Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01666756",
            "title": "Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2387,
                    "therapyName": "KD018 + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01687673",
            "title": "Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2388,
                    "therapyName": "Sorafenib + Temsirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01695005",
            "title": "A Study of LY3039478 in Participants With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2958,
                    "therapyName": "LY3039478",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01730937",
            "title": "Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01754987",
            "title": "A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01755767",
            "title": "Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 636,
                    "therapyName": "Tivantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01761266",
            "title": "A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 792,
                    "therapyName": "Lenvatinib",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01774344",
            "title": "Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (RESORCE)",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01775501",
            "title": "Sorafenib + mFOLFOX for Hepatocellular Carcinoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 1715,
                    "therapyName": "Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 1104,
                    "therapyName": "Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 1642,
                    "therapyName": "Leucovorin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01801163",
            "title": "A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01835223",
            "title": "Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot Be Removed by Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1055,
                    "therapyName": "Tivozanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01840592",
            "title": "Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2363,
                    "therapyName": "Doxorubicin + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01849588",
            "title": "Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C",
            "phase": "FDA approved",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01853618",
            "title": "Tremelimumab With Chemoembolization or Ablation for Liver Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1652,
                    "therapyName": "Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01887717",
            "title": "Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01900002",
            "title": "Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01908426",
            "title": "Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01915602",
            "title": "Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2221,
                    "therapyName": "Refametinib + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01966445",
            "title": "Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2919,
                    "therapyName": "GSK2849330",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01968109",
            "title": "Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 4196,
                    "therapyName": "Relatlimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01999738",
            "title": "Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1603,
                    "therapyName": "EC1456",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02024087",
            "title": "Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2364,
                    "therapyName": "Dalantercept + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02024607",
            "title": "A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1597,
                    "therapyName": "Capecitabine + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 2093,
                    "therapyName": "Bevacizumab + Napabucasin",
                    "synonyms": null
                },
                {
                    "id": 2094,
                    "therapyName": "Napabucasin + Regorafenib",
                    "synonyms": null
                },
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2057,
                    "therapyName": "Napabucasin",
                    "synonyms": null
                },
                {
                    "id": 1315,
                    "therapyName": "Fluorouracil + Irinotecan + Leucovorin",
                    "synonyms": "FOLFIRI"
                }
            ]
        },
        {
            "nctId": "NCT02069145",
            "title": "Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2413,
                    "therapyName": "Ipafricept + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02072486",
            "title": "Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02081755",
            "title": "Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer",
            "phase": null,
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1843,
                    "therapyName": "Tacrolimus",
                    "synonyms": null
                },
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02082210",
            "title": "A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1387,
                    "therapyName": "Emibetuzumab + Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02101593",
            "title": "Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2424,
                    "therapyName": "ADI-PEG 20",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02128958",
            "title": "Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7368,
                    "therapyName": "CF102",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02143401",
            "title": "Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1872,
                    "therapyName": "Navitoclax + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02151864",
            "title": "LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A Cirrhosis",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1428,
                    "therapyName": "Sonidegib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02174549",
            "title": "Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3028,
                    "therapyName": "tirapazamine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02178722",
            "title": "A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02227914",
            "title": "Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2422,
                    "therapyName": "Oprozomib",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02232633",
            "title": "A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1945,
                    "therapyName": "BBI503",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02279719",
            "title": "A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 2361,
                    "therapyName": "BBI503 + Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 2362,
                    "therapyName": "Napabucasin + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02288507",
            "title": "Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02292173",
            "title": "Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2197,
                    "therapyName": "Sorafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02314052",
            "title": "Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3122,
                    "therapyName": "DCR-MYC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02315066",
            "title": "Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4333,
                    "therapyName": "PF-04518600",
                    "synonyms": null
                },
                {
                    "id": 4448,
                    "therapyName": "PF-04518600 + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02323906",
            "title": "Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2430,
                    "therapyName": "CC-122 + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02406508",
            "title": "Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02423343",
            "title": "A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2409,
                    "therapyName": "Galunisertib",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02432963",
            "title": "Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5547,
                    "therapyName": "MVAp53 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02435433",
            "title": "A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 886,
                    "therapyName": "Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02460991",
            "title": "A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02508467",
            "title": "A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3165,
                    "therapyName": "BLU-554",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02509507",
            "title": "Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4035,
                    "therapyName": "Pembrolizumab + Talimogene laherparepvec",
                    "synonyms": null
                },
                {
                    "id": 2695,
                    "therapyName": "Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02519348",
            "title": "A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1652,
                    "therapyName": "Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02524119",
            "title": "LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma (LEE001)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 790,
                    "therapyName": "Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02528643",
            "title": "A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02540291",
            "title": "Study of E7046 in Subjects With Selected Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5694,
                    "therapyName": "E7046",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02560779",
            "title": "Trial of TRC105 and Sorafenib in Patients With HCC",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2389,
                    "therapyName": "Carotuximab + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02562755",
            "title": "Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3341,
                    "therapyName": "JX-594",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02564614",
            "title": "A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3612,
                    "therapyName": "EZN-2968",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02572687",
            "title": "A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3257,
                    "therapyName": "Durvalumab + Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02575339",
            "title": "MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02576509",
            "title": "A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02595866",
            "title": "Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02597036",
            "title": "A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3562,
                    "therapyName": "LY3127804",
                    "synonyms": null
                },
                {
                    "id": 886,
                    "therapyName": "Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02638909",
            "title": "Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 789,
                    "therapyName": "Ceritinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02642913",
            "title": "Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02658019",
            "title": "Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02675946",
            "title": "Study of CGX1321 in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6584,
                    "therapyName": "CGX1321",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02702401",
            "title": "Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02702414",
            "title": "Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02715531",
            "title": "A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 8305,
                    "therapyName": "Atezolizumab + Cisplatin + Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 3947,
                    "therapyName": "Atezolizumab + Gemcitabine + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 5126,
                    "therapyName": "Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 4595,
                    "therapyName": "Atezolizumab + Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 6275,
                    "therapyName": "Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin",
                    "synonyms": "Atezolizumab + FOLFOX"
                }
            ]
        },
        {
            "nctId": "NCT02795429",
            "title": "Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2659,
                    "therapyName": "Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 4492,
                    "therapyName": "Capmatinib + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02821754",
            "title": "A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02834780",
            "title": "Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6610,
                    "therapyName": "H3B-6527",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02837029",
            "title": "Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02842125",
            "title": "Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8315,
                    "therapyName": "Ad5CMV-p53 gene + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 5879,
                    "therapyName": "Ad5CMV-p53 gene + Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 7042,
                    "therapyName": "Ad5CMV-p53 gene + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02859324",
            "title": "A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4611,
                    "therapyName": "CC-122 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02867592",
            "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02906397",
            "title": "A Phase I Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2409,
                    "therapyName": "Galunisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02939807",
            "title": "A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3301,
                    "therapyName": "ABC294640",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02940496",
            "title": "Pembrolizumab (MK-3475) in Hepatocellular Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02947165",
            "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5632,
                    "therapyName": "NIS793 + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 5631,
                    "therapyName": "NIS793",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02960594",
            "title": "hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5844,
                    "therapyName": "INO-1400 + INO-9012",
                    "synonyms": null
                },
                {
                    "id": 5807,
                    "therapyName": "INO-1400",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02988440",
            "title": "Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5590,
                    "therapyName": "Sorafenib + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02989870",
            "title": "Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 5138,
                    "therapyName": "Bavituximab + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03006926",
            "title": "A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03037437",
            "title": "Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1208,
                    "therapyName": "Hydroxychloroquine + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03059147",
            "title": "A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 915,
                    "therapyName": "SF1126",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03095781",
            "title": "Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5533,
                    "therapyName": "Pembrolizumab + XL888",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03099564",
            "title": "Pembrolizumab Plus Y90 Radioembolization in HCC Subjects",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03132792",
            "title": "AFPc332T in Advanced HCC",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7367,
                    "therapyName": "AFPc332T",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03143270",
            "title": "A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03144661",
            "title": "An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5832,
                    "therapyName": "INCB062079",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03145558",
            "title": "TATE Versus TACE in Intermediate Stage HCC (TATE)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 3028,
                    "therapyName": "tirapazamine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03203304",
            "title": "Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03211416",
            "title": "Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6041,
                    "therapyName": "Pembrolizumab + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03222076",
            "title": "Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03253289",
            "title": "Meclizine for Hepatocellular Carcinoma (OPTIM)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9706,
                    "therapyName": "Meclizine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03257761",
            "title": "Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6146,
                    "therapyName": "Durvalumab + Guadecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03259867",
            "title": "Combination of TATE and PD-1 Inhibitor in Liver Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03289962",
            "title": "A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6234,
                    "therapyName": "RO7198457",
                    "synonyms": null
                },
                {
                    "id": 6235,
                    "therapyName": "Atezolizumab + RO7198457",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03298451",
            "title": "Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03299946",
            "title": "Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2067,
                    "therapyName": "Cabozantinib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03316222",
            "title": "Study of GNS561 in Patients With Liver Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 6985,
                    "therapyName": "GNS561",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03316872",
            "title": "Study of Pembrolizumab and Radiotherapy in Liver Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03318562",
            "title": "A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4005,
                    "therapyName": "Tomivosertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03319459",
            "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6375,
                    "therapyName": "FATE-NK100",
                    "synonyms": null
                },
                {
                    "id": 6376,
                    "therapyName": "FATE-NK100 + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 6377,
                    "therapyName": "Cetuximab + FATE-NK100",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03347292",
            "title": "Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7046,
                    "therapyName": "Pembrolizumab + Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03382886",
            "title": "Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma (NUANCE)",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2111,
                    "therapyName": "Bevacizumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03383458",
            "title": "A Phase 3 Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03412773",
            "title": "Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5871,
                    "therapyName": "BGB-A317",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03416335",
            "title": "A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8822,
                    "therapyName": "DSP-0509",
                    "synonyms": null
                },
                {
                    "id": 8823,
                    "therapyName": "DSP-0509 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03419897",
            "title": "Study of BGB-A317 in Patients With Previously Treated Unresectable HCC",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5871,
                    "therapyName": "BGB-A317",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03433703",
            "title": "Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 792,
                    "therapyName": "Lenvatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03434379",
            "title": "A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150]",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4595,
                    "therapyName": "Atezolizumab + Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03439891",
            "title": "Sorafenib and Nivolumab as First-Line Therapy in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6779,
                    "therapyName": "Nivolumab + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03441100",
            "title": "TCR-engineered T Cells in NSCLC and HCC Patients",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                },
                {
                    "id": 6783,
                    "therapyName": "IMA202",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03482102",
            "title": "Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03511222",
            "title": "Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6917,
                    "therapyName": "Pembrolizumab + Vorolanib",
                    "synonyms": null
                },
                {
                    "id": 6916,
                    "therapyName": "Nivolumab + Vorolanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03517488",
            "title": "A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6973,
                    "therapyName": "XmAb20717",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03519997",
            "title": "A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6919,
                    "therapyName": "Bavituximab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03533582",
            "title": "Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8240,
                    "therapyName": "Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 6946,
                    "therapyName": "Cisplatin + Doxorubicin + Fluorouracil + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 8242,
                    "therapyName": "Carboplatin + Cisplatin + Doxorubicin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 8241,
                    "therapyName": "Carboplatin + Cisplatin + Doxorubicin + Irinotecan + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 6951,
                    "therapyName": "Cisplatin + Doxorubicin + Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 6947,
                    "therapyName": "Cisplatin + Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 8243,
                    "therapyName": "Carboplatin + Cisplatin + Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03538028",
            "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6977,
                    "therapyName": "INCAGN02385",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03539822",
            "title": "Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7108,
                    "therapyName": "Cabozantinib + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03563170",
            "title": "QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 7060,
                    "therapyName": "Aldoxorubicin + ALT-803 + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Sorafenib",
                    "synonyms": "NANT hepatocellular carcinoma vaccine combination"
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03582618",
            "title": "CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7112,
                    "therapyName": "CVM-1118 + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03637764",
            "title": "Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7075,
                    "therapyName": "Atezolizumab + Isatuximab",
                    "synonyms": null
                },
                {
                    "id": 6331,
                    "therapyName": "Isatuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03638141",
            "title": "CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03647163",
            "title": "Combination Therapy With Intravenous VSV-IFNbeta-NIS and Pembrolizumab in Refractory NSCLC and HCC",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7449,
                    "therapyName": "Pembrolizumab + VSV-hIFNbeta-NIS",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03655002",
            "title": "IRX-2, Cyclophosphamide, and Nivolumab in Treating Participants With Recurrent or Metastatic and Refractory Liver Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7122,
                    "therapyName": "Cyclophosphamide + IRX-2 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03656718",
            "title": "A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7453,
                    "therapyName": "Nivolumab + rHuPH20",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03680508",
            "title": "TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7522,
                    "therapyName": "TSR-022 + TSR-042",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03684811",
            "title": "A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7527,
                    "therapyName": "Cisplatin + FT-2102 + Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 4449,
                    "therapyName": "Azacitidine + FT-2102",
                    "synonyms": null
                },
                {
                    "id": 4336,
                    "therapyName": "FT-2102",
                    "synonyms": null
                },
                {
                    "id": 7526,
                    "therapyName": "FT-2102 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03695250",
            "title": "BMS-986205 and Nivolumab as First Line Therapy in Treating Patients With Liver Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3569,
                    "therapyName": "BMS-986205 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03713593",
            "title": "Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 792,
                    "therapyName": "Lenvatinib",
                    "synonyms": null
                },
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03735628",
            "title": "An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6899,
                    "therapyName": "Copanlisib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03752398",
            "title": "A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9200,
                    "therapyName": "XmAb23104",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03755791",
            "title": "Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 6094,
                    "therapyName": "Atezolizumab + Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03778957",
            "title": "A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 2117,
                    "therapyName": "Bevacizumab + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03781960",
            "title": "Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 7451,
                    "therapyName": "Abemaciclib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03785210",
            "title": "Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7658,
                    "therapyName": "Nivolumab + Tadalafil + Vancomycin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03812562",
            "title": "Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03816345",
            "title": "Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03821935",
            "title": "Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7795,
                    "therapyName": "ABBV-151",
                    "synonyms": null
                },
                {
                    "id": 7796,
                    "therapyName": "ABBV-151 + ABBV-181",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03829501",
            "title": "Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7826,
                    "therapyName": "Atezolizumab + KY1044",
                    "synonyms": null
                },
                {
                    "id": 7825,
                    "therapyName": "KY1044",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03836352",
            "title": "Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7861,
                    "therapyName": "DPX-Survivac + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 5266,
                    "therapyName": "Cyclophosphamide + DPX-Survivac + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03847428",
            "title": "Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                },
                {
                    "id": 2117,
                    "therapyName": "Bevacizumab + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03849469",
            "title": "A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7902,
                    "therapyName": "Pembrolizumab + XmAb22841",
                    "synonyms": null
                },
                {
                    "id": 7901,
                    "therapyName": "XmAb22841",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03867084",
            "title": "Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03916627",
            "title": "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5656,
                    "therapyName": "Cemiplimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03936959",
            "title": "A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 9537,
                    "therapyName": "LY3434172",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03937830",
            "title": "Combined Treatment of Durvalumab, Bevacizumab, and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8362,
                    "therapyName": "Bevacizumab + Doxorubicin + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03964233",
            "title": "A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 and 754111",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5806,
                    "therapyName": "BI 754091 + BI 754111",
                    "synonyms": null
                },
                {
                    "id": 8524,
                    "therapyName": "BI 754091 + BI 754111 + BI 907828",
                    "synonyms": null
                },
                {
                    "id": 8525,
                    "therapyName": "BI 754091 + BI 907828",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03970616",
            "title": "A Study of Tivozanib in Combination With Durvalumab in Subjects With Untreated Advanced Hepatocellular Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8863,
                    "therapyName": "Durvalumab + Tivozanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03993873",
            "title": "Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8205,
                    "therapyName": "TPX-0022",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03998033",
            "title": "Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9666,
                    "therapyName": "ET140202",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04020185",
            "title": "Safety and Efficacy Study of IMSA101 in Refractory Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9540,
                    "therapyName": "IMSA101 + unspecified PD-L1 antibody",
                    "synonyms": null
                },
                {
                    "id": 9539,
                    "therapyName": "IMSA101 + unspecified PD-1 antibody",
                    "synonyms": null
                },
                {
                    "id": 9538,
                    "therapyName": "IMSA101",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04039607",
            "title": "A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 792,
                    "therapyName": "Lenvatinib",
                    "synonyms": null
                },
                {
                    "id": 920,
                    "therapyName": "Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04095273",
            "title": "Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8754,
                    "therapyName": "BAY1895344 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04096638",
            "title": "Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8759,
                    "therapyName": "Nivolumab + SB 11285",
                    "synonyms": null
                },
                {
                    "id": 8758,
                    "therapyName": "SB 11285",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04102098",
            "title": "A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4595,
                    "therapyName": "Atezolizumab + Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04114136",
            "title": "Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 5302,
                    "therapyName": "Metformin + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6581,
                    "therapyName": "Metformin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8813,
                    "therapyName": "Pembrolizumab + Rosiglitazone",
                    "synonyms": null
                },
                {
                    "id": 8812,
                    "therapyName": "Nivolumab + Rosiglitazone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04123379",
            "title": "Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5903,
                    "therapyName": "BMS-813160 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 6641,
                    "therapyName": "BMS-986253 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04134312",
            "title": "A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6889,
                    "therapyName": "MVA-BN-Brachyury",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04134559",
            "title": "Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04140526",
            "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8898,
                    "therapyName": "ONC-392",
                    "synonyms": null
                },
                {
                    "id": 8899,
                    "therapyName": "ONC-392 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04158700",
            "title": "A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 8926,
                    "therapyName": "LY3200882 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04175912",
            "title": "Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6501,
                    "therapyName": "Carboplatin + MLN4924 + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1688,
                    "therapyName": "MLN4924",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04204850",
            "title": "Cabozantinib to Treat of Recurrent Liver Cancer Post Transplant (CaboTx)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04250597",
            "title": "Study of GNX102 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9331,
                    "therapyName": "GNX102",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04260802",
            "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9335,
                    "therapyName": "OC-001 + unspecified PD-L1 antibody",
                    "synonyms": null
                },
                {
                    "id": 9334,
                    "therapyName": "OC-001 + unspecified PD-1 antibody",
                    "synonyms": null
                },
                {
                    "id": 9333,
                    "therapyName": "OC-001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04311710",
            "title": "A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U)",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 9635,
                    "therapyName": "Ipilimumab + Nivolumab + rHuPH20",
                    "synonyms": null
                }
            ]
        }
    ]
}